Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Samrat PharmachemBOM:530125 -0.69%69 5-Year Yield-on-Cost % is 0.43 as of Sep. 08, 2026, which is 59% above its 10-year median of 0.27. GuruFocus rates BOM:530125 with a GF Score™ of 69/100 and a GF Value™ of ₹355.67 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,029 Chemicals companies, Samrat Pharmachem ranks worse than 82.8% on this metric.
Samrat Pharmachem's yield on cost for the quarter that ended in Jun. 2026 was 0.43.
The historical rank and industry rank for Samrat Pharmachem's 5-Year Yield-on-Cost % or its related term are showing as below:
BOM:530125'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.09 Med: 0.27 Max: 0.51
Current: 0.43
During the past 13 years, Samrat Pharmachem's highest Yield on Cost was 0.51. The lowest was 0.09. And the median was 0.27.
BOM:530125's 5-Year Yield-on-Cost % is ranked worse than 82.8% of 1029
companies
in the Chemicals industry
Industry Median: 1.79
vs BOM:530125: 0.43
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Samrat Pharmachem 5-Year Yield-on-Cost % Related Terms
BOM:530125 vs DOW: 5-Year Yield-on-Cost % Comparison
For the Chemicals subindustry, Samrat Pharmachem's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Samrat Pharmachem 5-Year Yield-on-Cost % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Samrat Pharmachem's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Samrat Pharmachem's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Samrat Pharmachem (BOM:530125) has a 5-Year Yield-on-Cost % of 0.43 as of Sep. 08, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Samrat Pharmachem and its competitors. This is 59% above median its historical median of 0.27. Over the past decade, Samrat Pharmachem's 5-Year Yield-on-Cost % has ranged from 0.09 to 0.51. According to the industry distribution chart, Samrat Pharmachem ranks #852 out of 1029 companies in the Chemicals industry, placing it in the top 82.8%.
Is Samrat Pharmachem's 5-Year Yield-on-Cost % too high?
Samrat Pharmachem's current 5-Year Yield-on-Cost % of 0.43 is 59% above median its 10-year median of 0.27. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 0.51. The Chemicals industry median 5-Year Yield-on-Cost % is 1.79. Samrat Pharmachem's value of 0.43 is 76% below this industry median. Based on the distribution chart, Samrat Pharmachem ranks #852 out of 1029 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, Samrat Pharmachem has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Samrat Pharmachem's 5-Year Yield-on-Cost % compare to DOW?
According to the Chemicals industry distribution chart, Samrat Pharmachem ranks #852 out of 1029 companies for 5-Year Yield-on-Cost %. This places Samrat Pharmachem in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.79. Samrat Pharmachem's value of 0.43 is 76% below this benchmark. Historically, Samrat Pharmachem's own 5-Year Yield-on-Cost % has ranged from 0.09 to 0.51 over the past decade. While the company's 10-year median is 0.27 vs. the industry median of 1.79, Samrat Pharmachem has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Chemicals company?
The median 5-Year Yield-on-Cost % among Chemicals companies is 1.79, based on 1,029 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Samrat Pharmachem's current 5-Year Yield-on-Cost % of 0.43 is 76% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Samrat Pharmachem and its competitors. For the Chemicals industry, the median 5-Year Yield-on-Cost % is 1.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Samrat Pharmachem's current 5-Year Yield-on-Cost % is 0.43, which is 59% above median its own 10-year median of 0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Samrat Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Samrat Pharmachem (BOM:530125) is currently considered Possible Value Trap. The stock's GF Value™ is ₹355.67, compared to a current price of ₹229.90 — trading 35.4% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.43, which is 59% above median its 10-year median of 0.27 and 76% below the Chemicals industry median of 1.79. Samrat Pharmachem's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Samrat Pharmachem (BOM:530125), the current 5-Year Yield-on-Cost % is 0.43 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Samrat Pharmachem (BOM:530125) Overvalued in 2026?
Based on GuruFocus' analysis, Samrat Pharmachem stock appears to be undervalued.
The current stock price of ₹229.90 is trading 35.4% below its estimated GF Value™ of ₹355.67.
GuruFocus considers Samrat Pharmachem to be Possible Value Trap.
Key valuation signals for BOM:530125:
5-Year Yield-on-Cost %: 0.43 (59% above median its 10-year median of 0.27)
GF Value™: ₹355.67 vs. price of ₹229.90 (35.4% below fair value)
Industry Position: 76% below the Chemicals median (#852 of 1029)
No single metric tells the full story. See the BOM:530125 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Samrat Pharmachem Ltd is a producer of pharmaceutical chemicals. The principal activity of the company is to manufacture Iodine salts and bromine salts. Its product portfolio consists of potassium iodate, potassium iodide, methyl iodide, and copper iodide. Its products are used in various industries like pharmaceuticals and chemicals.
69GF Score
Get the complete analysis for BOM:530125
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530125 has been successfully added to your 
